Able VP joins Lachman
Executive Summary
Former Able Labs VP-Regulatory Affairs Joan Janulis joins the consulting firm as director of the regulatory group practice. Prior to joining Able in September 2004, Janulis served as VP-regulatory affairs for Alpharma from 2001 to 2004, where she helped secure the first approval for generic gabapentin capsules (Pfizer's Neurontin). Able voluntarily withdrew all of its products in May due to data integrity concerns and decided to sell its businesses and assets after FDA rejected the company's return-to-market plan in July (1"The Pink Sheet" Aug. 22, 2005, In Brief). The ANDAs involved in the data integrity issues were submitted prior to Janulis' employment at Able...
You may also be interested in...
Able to divest businesses
FDA rejects Able Labs' plan to return drugs to market by re-validating product development data included in existing ANDAs and says the company would need to resubmit the ANDAs to FDA for a complete review with new data. The process would take up to 18 months, leading Able to state that its plan for reorganization is not feasible. Able plans to sell its businesses to one or more third party purchasers rather than resume manufacturing. Problems stem from an FDA inspection showing Able did not meet established good manufacturing processes; the company announced a voluntary recall of its products in May (1"The Pink Sheet" May 20, 2005, p. 23)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.